Glenmark Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, plans to open its first US manufacturing facility in Monroe, North Carolina on October 30, 2018.

The Monroe, North Carolina facility is Glenmark’s first manufacturing site in the US and is designed to manufacture a variety of fixed-dose pharmaceutical formulations.Currently, the site has nearly 140 employees. Glenmark invested more than $100 million into the facility and has plans for further expansion in the coming years, according to the company.At peak capacity, the company says the site is anticipated to produce 300 million to 400 million tablets and capsules, 20 million to 25 million vials and prefilled syringes, and 25 million to 30 million ampuls for inhaled formulations.

Globally, Glenmark has 16 manufacturing facilities in Europe, India, and the US, which operate under GMP.

Source: Glenmark Pharmaceuticals